Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Savarese

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Alimentary Pharmacology & Therapeutics|July 18, 2006
Oesophageal acid exposure and altered neurocardiac function in patients with GERD and idiopathic cardiac dysrhythmiasR Cuomo, F De Giorgi, L Adinolfi, et al.
Gut|December 15, 2015
Split-dose preparation for colonoscopy increases adenoma detection rate: a randomised controlled trial in an organised screening programmeF Radaelli, S Paggi, C Hassan, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Alimentary Pharmacology & Therapeutics|July 18, 2006
Oesophageal acid exposure and altered neurocardiac function in patients with GERD and idiopathic cardiac dysrhythmiasR Cuomo, F De Giorgi, L Adinolfi, et al.
Gut|December 15, 2015
Split-dose preparation for colonoscopy increases adenoma detection rate: a randomised controlled trial in an organised screening programmeF Radaelli, S Paggi, C Hassan, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Pageof 2